Antibiotic Use in Children - Off-Label Use

被引:10
|
作者
Zingg, Walter [1 ]
Posfay-Barbe, Klara M. [2 ]
机构
[1] Univ Hosp Geneva, Infect Control Program, CH-1211 Geneva 14, Switzerland
[2] Univ Hosp Geneva, Dept Pediat, CH-1211 Geneva 14, Switzerland
关键词
Antibiotic therapy; children; infants; neonates; off-label use; off-licensed; unlicensed; ADVERSE DRUG-REACTIONS; MEDICATION USE; PEDIATRIC OUTPATIENTS; HOSPITALIZED CHILDREN; UNLICENSED USE; RENAL-FUNCTION; MEDICINES; INFANTS; PHARMACOKINETICS; DAPTOMYCIN;
D O I
10.2174/138945012800675777
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Systemic antibiotics are the group of drugs most commonly used in children. Off-label antibiotic use in children is still common in the community and in hospitals, mostly because of young age, dosage, or frequency of drug application. There is an important incentive gap that hinders paediatric drug development resulting from a series of factors, such as small market size, a predominance of off-patent use, no incentives for generic drug manufacturers, and a greater complexity of drug development. The latter is due to varying capacities of drug absorption and metabolism during growth and maturation and the need for oral formulations in neonates and infants. High ethical barriers, combined with concerns of parents about drug safety, further complicate the conduct of clinical studies in children. While many off-patent antibiotics today are labelled for use in children, newer substances such as fluoroquinolones, azithromycin, linezolid, or daptomycin are not. This is of concern in the light of emerging multidrug-resistant pathogens.
引用
收藏
页码:885 / 892
页数:8
相关论文
共 50 条
  • [41] Methylphenidate Off-label Use
    Trenque, T.
    DRUG SAFETY, 2012, 35 (10) : 891 - 891
  • [42] Off-label use in neurology
    Diener, HC
    AKTUELLE NEUROLOGIE, 2002, 29 (08) : 379 - 381
  • [43] A Hemorrhage of Off-Label Use
    Avorn, Jerry
    Kesselheim, Aaron
    ANNALS OF INTERNAL MEDICINE, 2011, 154 (08) : 566 - 567
  • [44] QUETIAPINE OFF-LABEL USE
    Levin, R.
    Cosmatos, I
    Dieck, G.
    Reifsnyder, J.
    VALUE IN HEALTH, 2016, 19 (07) : A522 - A522
  • [45] Off-label use of vaccines
    Neels, Pieter
    Southern, James
    Abramson, Jon
    Duclos, Philippe
    Hombach, Joachim
    Marti, Melanie
    Fitzgerald-Husek, Alanna
    Fournier-Caruana, Jacqueline
    Hanquet, Germaine
    VACCINE, 2017, 35 (18) : 2329 - 2337
  • [46] Off-label use of infliximab
    Onder, M.
    Salavastru, C.
    Fritz, K.
    HAUTARZT, 2013, 64 (10): : 757 - 761
  • [47] Off-label antibiotic use in a specialized children care hospital in Punjab, Pakistan: Findings and implications
    Hafeez, Muhammad
    Saleem, Zikria
    Bukhari, Nasir Abbas
    Hussain, Khalid
    Shamim, Rahat
    Hussain, Amjad
    Bukhari, Nadeem Irfan
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2020, 14 (05): : 540 - 544
  • [48] Off-label use in psychopharmacotherapy [Off-Label-Use in der Psychopharmakotherapie]
    Fritze J.
    Schmauss M.
    Der Nervenarzt, 2002, 73 (8) : 796 - 799
  • [49] Off-Label Use of rFVIIa in Children With Excessive Bleeding: A Consecutive Study of 153 Off-Label Uses in 139 Children
    Young, Guy
    Wicklund, Brian
    Neff, Philip
    Johnson, Chelsea
    Nugent, Diane J.
    PEDIATRIC BLOOD & CANCER, 2009, 53 (02) : 179 - 183
  • [50] Off-Label Use vs Off-Label Marketing of Drugs Part 1: Off-Label Use-Patient Harms and Prescriber Responsibilities
    Van Norman, Gail A.
    JACC-BASIC TO TRANSLATIONAL SCIENCE, 2023, 8 (02): : 224 - 233